glp-1 obesity drug news updates The next phase of the race Use of diabetes and anti-obesity

Antiamyloid therapies have recently changed the treatment landscape

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

CBS News medical correspondent Dr

Connect with certified providers on Meto for personalized support and results

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d

This interaction triggers multiple beneficial effects, such as enhancing insulin release from the pancreas when glucose levels are high, suppressing glucagon (which raises blood sugar), and signaling the brain to promote fullness